Openbookopenbook
Equity
Nascent Biotech Inc(NBIO)
USD --+0.00%
Reward38Moderate
Risk75High
📊75%Data
Revenue down 100% YoY
NBIO
+0.0 · +0.00%
USD · OTCQB
Nascent Biotech Inc | Healthcare
Earnings Deterioration
Market Cap:51665
ℹ️
Reward Rating
38
Moderate
Bottom 5% (model universe)
75% data coverage
ℹ️
Risk Rating
75
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on NBIO to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Nascent Biotech Inc?

, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer.

NBIO · Verdict

Limited reward · high risk

NBIO has limited near-term tailwinds — cash flow and profitability weigh on the model output.

Based on 88% data coverage

NBIO · Verdict

What’s working & what to watch

Watchouts 4

  • Cash flow5/100

    Weak vs peers

  • Profitability10/100

    0% return on equity

  • Volatility20/100

    Weak vs peers

  • Growth41/100

    Earnings +29.6% CAGR

Model-based scoring. For information only — not financial advice.

What is Nascent Biotech Inc?

, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is listed on the OTCQB in USA, operating in the Healthcare sector, with a market capitalisation of 51.66K.

Financial Highlights

Investment Breakdown

📈 Growth
Growth trend is developing — watch for revenue consistency over upcoming quarters.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Elevated volatility implies higher downside and expectation risk.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (38)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap51.66K
P/E RatioN/A
Dividend YieldN/A
52 Week High0.084
52 Week Low0.0001
Last AnnualMarch
IPO DateN/A
IncorporatedUSA
Shares Outstanding172M
No. of EmployeesN/A
IndustryBiotechnology
ExchangeOTCQB
Beta1.952
CurrencyUSD
Websitewww.nascentbiotech.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.